
The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood CirculationAward last edited on: 2/27/2019
Sponsored Program
SBIRAwarding Agency
NIH : NCITotal Award Amount
$298,444Award Phase
1Solicitation Topic Code
-----Principal Investigator
Annette MarleauCompany Information
Aethlon Medical Inc (AKA: Bishop Equities Inc)
11555 Sorrento Valley Road Suite 203
San Diego, CA 92121
San Diego, CA 92121
(619) 941-0360 |
info@aethlonmedical.com |
www.aethlonmedical.com |
Location: Multiple
Congr. District: 50
County: San Diego
Congr. District: 50
County: San Diego
Phase I
Contract Number: ----------Start Date: ---- Completed: ----
Phase I year
2018Phase I Amount
$298,444Project Terms:
Achievement; Address; Affinity; Agglutinins; base; Blood; Blood Circulation; Breast Cancer Cell; Breast Cancer cell line; Breast Cancer Patient; Breast Cancer Treatment; Cancer Patient; Cell Culture Techniques; Cells; chemotherapeutic agent; Clinical; Clinical Trials; CSPG4 gene; design; Development; Device Designs; Devices; Disease; ERBB2 gene; Evaluation; Excision; exosome; experimental study; FDA approved; Feasibility Studies; Flow Cytometry; Galanthus nivalis; glycosylation; Goals; Hematopoietic Neoplasms; Hemodialysis; Hemofiltration; Hour; Human; Immune; immune function; Immunophenotyping; Immunosuppression; improved; Individual; insight; interest; Laboratories; Lectin; Life; Lymphocyte; magnetic beads; Malignant - descriptor; malignant breast neoplasm; Malignant Neoplasms; Mediating; Medical Device; Methods; Modeling; Molecular Sieve Chromatography; nanosized; nanovesicle; Natural Killer Cells; Neoplasm Metastasis; neoplastic cell; Non-Malignant; Oncogenic; oncology; Oncoproteins; overexpression; Parents; Pathway interactions; Patients; Pharmaceutical Preparations; Phase; Phenotype; Plasma; Plasmapheresis; Population; prospective; Protocols documentation; Research; research study; Research Support; Role; SLEB2 gene; standard of care; Stromal Cells; Stromal Neoplasm; success; Surface; Survival Rate; T-Lymphocyte; targeted treatment; Testing; Therapeutic; Therapeutic Monoclonal Antibodies; therapy resistant; Tissues; TNFSF10 gene; Treatment Protocols; tumor; tumor growth; Tumor-Derived; Universities; Ursidae Family; Validation; Vesicle; Virus;
Phase II
Contract Number: ----------Start Date: ---- Completed: ----